Headlands Technologies LLC Has $772,000 Stock Position in Agios Pharmaceuticals, Inc. $AGIO

Key Points

• Headlands Technologies cut its Agios Pharmaceuticals stake by 64.9% in the second quarter, leaving it with 20,805 shares valued at approximately $772,000. Other major investors, including BlackRock, State Street and Wellington Management, increased their positions.
• Analysts remain broadly positive on AGIO, with a consensus rating of “Moderate Buy” and an average price target of $41.25. Several firms raised their targets, although JPMorgan maintained a neutral rating and Truist lowered its target.
• Agios shares opened at $34.21, while the company reported a quarterly loss of $1.69 per share—slightly worse than expected—despite revenue of $44.75 million exceeding analyst estimates. The stock has traded between $22.24 and $46.00 over the past year.

Headlands Technologies LLC cut its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 64.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,805 shares of the biopharmaceutical company's stock after selling 38,452 shares during the period. Headlands Technologies LLC's holdings in Agios Pharmaceuticals were worth $772,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in AGIO. BlackRock Inc. acquired a new position in Agios Pharmaceuticals during the 2nd quarter valued at about $239,582,000. Bellevue Group AG increased its holdings in Agios Pharmaceuticals by 3.5% during the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company's stock worth $149,110,000 after purchasing an additional 124,586 shares in the last quarter. State Street Corp raised its stake in shares of Agios Pharmaceuticals by 37.4% in the fourth quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company's stock worth $84,604,000 after purchasing an additional 845,433 shares during the last quarter. Erste Asset Management GmbH lifted its holdings in shares of Agios Pharmaceuticals by 1.4% in the fourth quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company's stock valued at $76,343,000 after purchasing an additional 40,000 shares in the last quarter. Finally, Wellington Management Group LLP lifted its holdings in shares of Agios Pharmaceuticals by 485.5% in the third quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company's stock valued at $99,203,000 after purchasing an additional 2,049,287 shares in the last quarter.

Analyst Ratings Changes

Several brokerages recently issued reports on AGIO. Bank of America upped their price target on Agios Pharmaceuticals from $40.00 to $46.00 and gave the stock a "buy" rating in a report on Tuesday, July 7th. JPMorgan Chase & Co. raised their price objective on Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday, August 7th. HC Wainwright lifted their price objective on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a "buy" rating in a report on Thursday, July 30th. Truist Financial reduced their target price on shares of Agios Pharmaceuticals from $41.00 to $39.00 and set a "buy" rating for the company in a research note on Friday, July 31st. Finally, Citigroup upped their target price on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $41.25.

Agios Pharmaceuticals Stock Up 1.6%

Shares of NASDAQ AGIO opened at $34.21 on Wednesday. The company has a market capitalization of $2.04 billion, a PE ratio of -4.88 and a beta of 0.60. The stock's 50 day moving average price is $35.84 and its 200-day moving average price is $31.75. Agios Pharmaceuticals, Inc. has a twelve month low of $22.24 and a twelve month high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts' consensus estimates of ($1.65) by ($0.04). The business had revenue of $44.75 million for the quarter, compared to analysts' expectations of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. As a group, research analysts expect that Agios Pharmaceuticals, Inc. will post -5.82 EPS for the current fiscal year.

Insider Activity

In other news, insider Sarah Gheuens sold 30,000 shares of the firm's stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total transaction of $914,400.00. Following the completion of the sale, the insider directly owned 54,645 shares of the company's stock, valued at $1,665,579.60. This trade represents a 35.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is currently owned by corporate insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source